Long-term Low-Dose Cabergoline Usage: Another Association with Cardiac Valvulopathy

Authors

Steven Tessier, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA
Brooke A. Lipton, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA
Mohammad I. Arastu, Department of Internal Medicine, St. Luke's Health Network, Bethlehem, Pennsylvania, USA
Andrew M. Curiale, Department of Cardiology, St. Luke's University Health Network, Bethlehem, Pennsylvania, USA
Santo Longo, Department of Pathology, St. Luke's University Health Network, Bethlehem, Pennsylvania, USA
Sudip Nanda, Department of Cardiology, St. Luke's University Health Network, Bethlehem, Pennsylvania, USA

Document Type

Article

Abstract

A 60-year-old patient, professor of physics, presented in 1999 with sudden-onset vitiligo associated with hyperprolactinemia and a prolactinoma. Fearful of potential surgical complications at the peak of his career, the patient declined surgery and opted for medical management with bromocriptine. The decreasing effectiveness of bromocriptine after 5 years required a switch to cabergoline. After a 15-year-course of cabergoline therapy with a cumulative dose of 572 mg, echocardiographic monitoring demonstrated aortic and mitral valve thickening and regurgitation. An additional 3 years of cabergoline treatment (cumulative dose: 649 mg) resulted in worsening valve thickening and regurgitation. It is well-recognized that such valvular changes may occur with high-dose cabergoline treatment. We report a case of mitral and aortic vavulopathy in a patient who was treated with long-term (18 years) low-dosage (.5–1 mg weekly) cabergoline.

First Page

61

Last Page

64

DOI

10.1111/echo.15506

Publication Date

1-2023

Recommended Citation

Tessier S, Lipton BA, Arastu MI, Curiale AM, Longo S, Nanda S. Long‐term low‐dose cabergoline usage: Another association with cardiac valvulopathy. Echocardiography. 2023 Jan;40(1):61-4.